European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Urine test shows promise in reducing post-op kidney cancer scans by half

A new urine test could reduce the need for routine CT scans after kidney cancer surgery by reliably ruling out recurrence, early results from a major international study show.

Tue, 25 Mar 2025
Kidney CancerEAU 25Biomarker
S. Dabestani, Lund (SE)
Enlarge image

A non-invasive urine test may soon transform how patients are monitored following surgery for clear cell renal cell carcinoma (ccRCC)—the most common form of kidney cancer. The findings, presented at the EAU25 Congress in Madrid and accepted for publication in European Urology Oncology, show that the test could safely reduce the number of post-operative scans by half.

How the GAGome test works

The test works by analysing glycosaminoglycans (GAGs)—a type of sugar molecule found in urine. These molecular profiles, referred to as the GAGome, are measured and assigned a score that can indicate whether the cancer has returned.

Initial results from the AURORAX-0087A (AUR87A) study, which includes patients across Europe and North America, show the GAGome test correctly identified 90% of patients with a recurrence, and ruled out cancer in 97% of those who remained disease-free. These results suggest the test has comparable accuracy to CT scans, which are currently the gold standard for monitoring recurrence.

“CT scans often pick up small findings we can’t yet interpret, which can lead to unnecessary stress and extra follow-ups,” said Assoc. Prof. Saeed Dabestani (Lund University, Sweden), the study’s lead investigator. “If we can reliably use a urine test to rule out recurrence, then we could safely reduce scan frequency—potentially cutting the number of scans in half.”

The first study cohort involved 134 patients with non-metastatic ccRCC treated with surgery at 23 centres in the UK, EU, USA, and Canada. All patients continued regular CT scans while also providing a urine sample every three months. Samples were scored using mass spectrometry, with a score above 12 considered a positive result. A positive test gave a 26% chance of actual recurrence, while a negative score came with a 97% certainty of no recurrence.

Expert insights

The test's high negative predictive value is especially promising, says Dr Carmen Mir Maresma (University Hospitals La Ribera, Spain), a member of the EAU Scientific Congress Office. “If the test comes back negative, you can be fairly confident the cancer hasn’t returned. That could be hugely beneficial in reassuring patients and reducing unnecessary imaging.”

The study is still ongoing, with a second patient cohort currently being recruited to validate the results. Final data from this next phase are expected later in 2025. The test itself, developed by Swedish diagnostics company Elypta, is not yet approved for clinical use and will require further validation before widespread implementation.

As new treatments like immunotherapy (e.g., pembrolizumab) are increasingly used after surgery, researchers also aim to explore how this urine-based biomarker may interact with evolving therapeutic strategies.

To learn more, watch the full EAU-TV interview from EAU25 where Dr. Carmen Mir speaks with Assoc. Prof. Saeed Dabestani about the study.

More information

Read the press release here.
Watch the webcast of the presentation here.

Share this article

Suggested for you

See all
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer